RIDDLE&CODE
5.4.2022 10:17:07 CEST | Business Wire | Press release
RIDDLE&CODE Energy Solutions, a 50:50 joint venture between Wien Energie and RIDDLE&CODE, has joined the 2Tokens consortium as a founding member for the Energy Token working group. After having been an associated partner since 2020, the company’s decision to become an active contributor is a consequent step on its path to developing an international service portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005131/en/
The main goal of the collaboration is to turn 2Tokens into the leading European consortium in the industrial blockchain and finance space, representing and supporting the most relevant projects. "We have proven the technical and economic viability of tokenizing energy assets in several individual projects at the regional level. Now it is time to think on a larger scale. The token standards being developed at 2Tokens will most likely have a decisive impact on the future standards of the European energy market,” says Kai Siefert, the newly appointed managing director of RIDDLE&CODE Energy Solutions.
“The joining of a true pioneer such as RIDDLE&CODE Energy Solutions will significantly strengthen European collaboration in the tokenization sector,” underlines Alex Bausch, Executive Chairman of 2Tokens. “RIDDLE&CODE Energy Solutions plays an important role in the adoption of tokenization technology in commercial projects with interoperable banking grade solutions. Our working groups on the EURO stable coin and Energy Tokens are paramount to the joint mission for mass adoption of token technology in the energy industry. “
Next steps: Apart from driving things forward in the 2Tokens working groups, leading 2Tokens members, as well as the RIDDLE&CODE group companies, will discuss commercial partnerships in the areas of Custody of Digital Assets, Tokenization platforms and blockchain hardware research. "For critical infrastructures and in order to turn our European values of democratic governance and the Rule of Law into efficient backend solutions, we need infrastructure that is secure from end-to-end. Crypto hardware anchors will play a key role in this, and that's why 2Tokens is excited to have RIDDLE&CODE joining as the leading European blockchain interface company,” says Jos Röling, Captain of the Energy working group.
About RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions provides the blockchain-powered infrastructure that enables resilient, decentralized and fully decarbonized energy markets. With the development of the MyPower platform, the company has shown an effective way for energy players to move into the machine economy. By tokenizing energy, machines, and data, RIDDLE&CODE Energy Solutions significantly increases the liquidity of distributed assets, making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
About 2Tokens
2Tokens has the ambition to raise awareness, stimulate relevant discussions, and bring together knowledge/expertise to reduce the barriers to the adoption of tokenization and help realise wider social benefits. The mission of 2Tokens is to formulate a guide, as part of a larger vision, for any type of organisation that wants to leverage token technology. It aims to come to a shared understanding of token finance and, as such, is a public-interest initiative supported by a diverse community of technology companies, policymakers, financial advisors, banks, and legal & regulatory experts and academia. 2Tokens is a non-profit organisation funded in part by the European Union and Industry partners with the endorsement of the Erasmus University Rotterdam, government and several industry players.
More information: www.2tokens.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom